A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

J Pritchard, IA Grau, ZR Idrissova, BR Lecky, Ian Sutton, AW Swan, HJ Willison, John Winer, RA Hughes

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Original languageEnglish
Pages (from-to)1282-4
Number of pages3
JournalNeurology
Volume61
Issue number9
Publication statusPublished - 1 Jan 2003

Fingerprint

Dive into the research topics of 'A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome'. Together they form a unique fingerprint.

Cite this